Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0H2JD
|
||||
Former ID |
DNCL002324
|
||||
Drug Name |
Gemcitabine prodrug
|
||||
Company |
Eli Lilly
|
||||
Target and Pathway | |||||
Target(s) | Ribonucleoside-diphosphatereductase subunit M2 | Target Info | Inhibitor | [528281] | |
Human DNA | Target Info | Inhibitor | [528281] | ||
BioCyc Pathway | Pyrimidine deoxyribonucleotides biosynthesis from CTP | ||||
Pyrimidine deoxyribonucleotides de novo biosynthesis | |||||
Guanosine nucleotides de novo biosynthesis | |||||
Superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis | |||||
Superpathway of purine nucleotide salvage | |||||
Purine nucleotides de novo biosynthesis | |||||
Adenosine deoxyribonucleotides de novo biosynthesis | |||||
Guanosine deoxyribonucleotides de novo biosynthesis | |||||
NetPath Pathway | EGFR1 Signaling Pathway | ||||
Pathway Interaction Database | E2F transcription factor network | ||||
PathWhiz Pathway | Purine Metabolism | ||||
Pyrimidine Metabolism | |||||
References | |||||
Ref 523989 | ClinicalTrials.gov (NCT01648764) A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread. U.S. National Institutes of Health. | ||||
Ref 531557 | Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors. Clin Cancer Res. 2011 Sep 15;17(18):6071-82. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.